UCI ¹ Comprehensive Cancer Center

Hepatobiliary and Pancreas Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

www.cancer.uci.edu

LOCOREGIONAL	FIRST LINE	SECOND LINE		THIRD LINE	
UCI 21-206/DOORwaY90 SIRT	UCI 22-106 STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab				
Coord: M. Duron Accrual: 3/10	Coord: H. Nguyen Accrual: 3/10				
UCI 20-84/Instylla Hydrogel embolic system vs SOC TAE/cTACE Coord: M. Duron Accrual: 8/13 UCI 19-49 Cabo + Ipi/Nivo + TACE	<u>UCI 22-211</u> MED1572 (IgG1 mAb) ± Bev ± Lenvatinib Coord: C. Kang Accrual: 1/8	UCI 23-58 Livmoniplimab + Budigalimab or Lenvatinib or Sorafenib Coord: H. Nguyen Accrual: 0/10	MPS1 – TTK Coord Accr	UCI 22-202 MPS1 – TTK kinase inhibitor Coord: C. Kang Accrual: 0/7	
	UCI 23-104 Livmoniplimab + Budigalimab Atezolizumab + Bevacizumab Tremelimumab + Durvalumab		<u>UCI 16-94</u> <u>TATE + Nivolumab (includes gastric/GEJ)</u> Coord: M. Duron Accrual: 24/40		
Coord: Han Nguyen Accrual: 15/35	IRB, budget, contract pending		UCI 23-24 HAI SD-101 + Pembrolizumab or Nivolumab		
	UCI 23-91 INCB099280 (Oral CPI) + Ipilimumab			d contract pending	
	IRB, budget, contract pending				
	UCI 23-86 Atezolizumab ± Bevacizumab (Child-Pugh B7 and B8)				




IRB, budget, contract pending



Coord: C. Kang Accrual: 1/8







S2001 Olaparib +/- Pembrolizumab (BRCA 1/2)

> Coord: J. Balangue Accrual: 2/4







ADJUVANT <u>S2104</u> <u>Capecitabine + Temozolomide</u>


vs observation

Pancreatic NET

Coord: J. Balangue Accrual: 0/2








Pending IRB/budget/contract

Solid Tumors Based Biomarker











PROGRESSED, ALL THERAPIES EXHAUSTED, OR NOT AMENABLE TO TREATMENT

SYSTEMIC AND/OR IO NAIVE

UCI 22-26 CB-03-10 (Androgen and glucocorticoid antagonist)

All solid tumors

Coord: N. Ferrand Accrual: 6/12

UCI 23-07 P-MUC1C-ALLO1 (CAR-T Cell)

> IRB, budget, contract pending

UCI 22-37 TACH101 (KDM4C inhibitor)

Phase 1: all solid tumors

Coord: A. Luna Accrual: 3/10

UCI 23-91 INCB099280 (Oral CPI) + Ipilimumab Phase 1: HCC, ccRCC, Melanoma, MSI-H/dMMR Colorectal Expansion: HCC, ccRCC, systemic and immunotherapy naive

IRB, budget, contract pending





Open to Accrual Low Accruing Pending Activation/Suspended

BLOOD COLLECTIONSUPPORTIVEUCI 21-124
ctDNA collection during HBP
workupUCI 22-109
Palonosetron IV vs. Buccal film
anti-emeticCoord: J. Balangue
Accrual: 10/15Coord: P. Yang
Accrual: 1/30

UCI 23-10/PRECEDE (Blood collection for early detection of pancreatic cancer)

Pending IRB

UCI 20-101 (Biospecimen Collection for patients planned to start IO treatment)

> Coord: J. Koff Accrual: 53/80



